Current Report Filing (8-k)
February 25 2021 - 6:07AM
Edgar (US Regulatory)
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
FORM
8-K
CURRENT
REPORT
PURSUANT
TO SECTION 13 OR 15(D) OF THE
SECURITIES
EXCHANGE ACT OF 1934
Date
of Report (Date of earliest event reported): February 24, 2021
INTERPACE
Biosciences, INC.
(Exact
name of Registrant as specified in its charter)
DELAWARE
|
|
0-24249
|
|
22-2919486
|
(State
or other jurisdiction
|
|
(Commission
|
|
(IRS
Employer
|
of
incorporation)
|
|
File
Number)
|
|
Identification
No.)
|
Morris
Corporate Center 1, Building C
300
Interpace Parkway,
Parsippany,
NJ 07054
(Address,
including zip code, of Principal Executive Offices)
(855)
776-6419
Registrant’s
telephone number, including area code
Not
Applicable
(Former
name or former address, if changed since last report)
Check
the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant
under any of the following provisions:
[ ]
|
Written
communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
|
|
[ ]
|
Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
|
|
[ ]
|
Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
|
|
[ ]
|
Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
Securities
registered pursuant to Section 12(b) of the Act: None.
Title
of each class
|
|
Trading
Symbol(s)
|
|
Name
of each exchange on which registered
|
None
|
|
N/A
|
|
N/A
|
Indicate
by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405
of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
[ ]
Emerging growth company
If
an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for
complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. [ ]
Item
3.01. Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing.
As
previously disclosed in Interpace Biosciences, Inc.’s (the “Company”) Current Report on Form 8-K
filed with the Securities and Exchange Commission (the “Commission”) on February 17, 2021, the Company
received a notification from The Nasdaq Stock Market (“Nasdaq”) indicating that, as a result of the
Company’s previously disclosed noncompliance with Nasdaq Listing Rules 5550(b), Nasdaq has determined to delist the Company’s
common stock from the Nasdaq Capital Market and, accordingly, will suspend trading in the Company’s common stock effective
at the open of business on February 25, 2021. The Company expects that Nasdaq will also file a Form 25-NSE with the Commission
to delist the Company from the Nasdaq Capital Market.
On
February 24, 2021, the Company was approved to have its common stock quoted on the OTCQX® Best Market tier of the
OTC Markets Group Inc. (the “OTCQX”), an electronic quotation service operated by OTC Markets Group
Inc. The Company expects that trading of the Company’s common stock will commence on OTCQX at the open of business on February
25, 2021 under the trading symbol IDXG.
Item
8.01. Other Events.
On
February 24, 2021, the Company issued a press release announcing that the Company was accepted for trading on OTCQX. The full
text of the press release is attached hereto as Exhibit 99.1 and is incorporated herein by reference.
Item
9.01. Financial Statements and Exhibits.
(d)
Exhibits.
SIGNATURE
Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf
by the undersigned hereunto duly authorized.
|
Interpace
Biosciences, Inc.
|
|
|
|
By:
|
/s/
Thomas W. Burnell
|
|
Name:
|
Thomas
W. Burnell
|
|
Title:
|
President
and Chief Executive Officer
|
Date:
February 25, 2021
Interpace Biosciences (NASDAQ:IDXG)
Historical Stock Chart
From Mar 2024 to Apr 2024
Interpace Biosciences (NASDAQ:IDXG)
Historical Stock Chart
From Apr 2023 to Apr 2024